ACTINIUM PHARMAC. DL-001
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patie… Read more
ACTINIUM PHARMAC. DL-001 (7AY1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ACTINIUM PHARMAC. DL-001 (7AY1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ACTINIUM PHARMAC. DL-001 - Net Assets Trend (None–None)
This chart illustrates how ACTINIUM PHARMAC. DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ACTINIUM PHARMAC. DL-001 (None–None)
The table below shows the annual net assets of ACTINIUM PHARMAC. DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ACTINIUM PHARMAC. DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ACTINIUM PHARMAC. DL-001 Competitors by Market Cap
The table below lists competitors of ACTINIUM PHARMAC. DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nusantara Pelabuhan Handal Tbk PT
JK:PORT
|
$29.71 Million |
|
Bhartiya International Limited
NSE:BIL
|
$29.72 Million |
|
Yesil Yatirim Holding AS
IS:YESIL
|
$29.72 Million |
|
The Environmental Group Limited
F:E7G
|
$29.72 Million |
|
Internet Thailand Public Company Limited
F:IE2A
|
$29.70 Million |
|
PB Bankshares Inc
NASDAQ:PBBK
|
$29.70 Million |
|
Master Style PCL
BK:MASTER
|
$29.69 Million |
|
Yatra Online Inc
NASDAQ:YTRA
|
$29.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ACTINIUM PHARMAC. DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ACTINIUM PHARMAC. DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ACTINIUM PHARMAC. DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ACTINIUM PHARMAC. DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ACTINIUM PHARMAC. DL-001 (7AY1) | €- | N/A | N/A | $29.71 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |